BioMarin Pharmaceutical (BMRN) is a Top-Ranked Growth Stock: Should You Buy?
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals.
Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is to use the Zacks Style Scores, which are indicators that rate stocks based on three widely-followed investing types: value, growth, and momentum.
Why This 1 Growth Stock Should Be On Your Watchlist
Growth investors build their portfolios around companies that are financially strong and have a bright future, and the Growth Style Score helps take projected and historical earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
BioMarin Pharmaceutical (BMRN)
San Rafael, CA-based BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for serious life-threatening medical conditions, mainly for children.
BMRN boasts a Growth Style Score of B and VGM Score of B, and holds a Zacks Rank #3 (Hold) rating. Its bottom-line is projected to rise 4.7% year-over-year for 2023, while Wall Street anticipates its top line to improve by 14.7%.
One analyst revised their earnings estimate upwards in the last 60 days for fiscal 2023. The Zacks Consensus Estimate has increased $0 to $2.02 per share. BMRN boasts an average earnings surprise of 11.7%.
On a historic basis, BioMarin Pharmaceutical has generated cash flow growth of 65.6%, and is expected to report cash flow expansion of 72.2% this year.
With solid fundamentals, a good Zacks Rank, and top-tier Growth and VGM Style Scores, BMRN should be on investors' short lists.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report
